Argenx stock holds near 12-month high as analysts update targets

Published on 09/10/2026 at 15:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Argenx stock closed at USD 1,007.07 on Nasdaq on September 9, 2026, keeping within reach of its 12-month high around USD 1,072.75. Recent Q2 2026 results showed double-digit revenue growth and updated guidance that analysts are factoring into fresh price targets.

Fotorealistisches Laborpanorama: Wissenschaftler in weißen Kitteln begutachten leuchtende Antikörper-3D-Modelle auf Bildschirmen, Stahltische mit Laborgeräten im Hintergrund — Argenx NL0010832176 Forscher analysieren im modernen Biopharma-Labor leuchtende Antikörper-Strukturen auf großen Monitoren, Illustration mit AI erstellt.

Argenx stock closed at USD 1,007.07 on the Nasdaq on September 9, 2026, down 2.52% from the prior close but still trading close to a reported 12-month high around USD 1,072.75 per recent Nasdaq-based market data summaries.

Q2 2026 results underpin Argenx stock

According to Argenx, the company reported its latest quarterly figures for the second quarter of 2026, providing the fundamental backdrop for the current valuation.

In that Q2 2026 report, Argenx stated that total revenue rose to USD 670.1 million, up 32.4 percent from USD 506.1 million in Q2 2025, reflecting continued uptake of its lead autoimmune therapy and expanding patient access programs.

Guidance and pipeline expectations

Argenx also updated its full-year 2026 guidance, indicating it now expects total revenue in a range of USD 2.55 billion to USD 2.65 billion, compared with the previously communicated corridor that had centered around USD 2.4 billion for the year, and projected an operating margin in the mid-20s percent supported by disciplined cost control.

As Investing.com reported on September 9, 2026, Argenx is expected to deliver Phase III data for its MMN program in the fourth quarter of 2026, a catalyst that many investors see as important for confirming long-term growth assumptions.

Analyst targets and valuation context

Based on an AI-driven comparison from Danelfin on September 10, 2026, Argenx SE carries an AI price target of USD 1,040.45 with a high forecast of USD 1,311.41 and a low forecast of USD 670.13, implying a potential upside of about 3.80 percent from the last observed price of USD 1,002.35.

The same analysis places that USD 1,002.35 Argenx price in the upper part of its recent trading range, with the upside to USD 1,040.45 relatively moderate compared with the distance to the high scenario of USD 1,311.41, highlighting that the market already prices in a substantial share of expected growth.

Stock near 12-month high and market metrics

Per a recent market overview that cited Nasdaq and CompaniesMarketCap data, Argenx SE (ISIN NL0010832176, Nasdaq ticker ARGX) finished trading at USD 1,007.07 on September 9, 2026, after previously closing at USD 1,033.15 on September 4, 2026, marking a decline of USD 26.08 over the latest completed session and leaving the shares within touching distance of the 12-month high of about USD 1,072.75.

The same overview indicated that Argenx carried a market capitalization of roughly USD 62.20 billion at the end of trading on September 9, 2026, underscoring how the stock sits among the larger biopharmaceutical names in its peer group at this valuation level.

Closing price and investor angle

Argenx stock thus stands at USD 1,007.07 on the Nasdaq as of September 9, 2026, in United States dollars, with that close near the upper end of its recent range and not far below the reported 12-month high around USD 1,072.75, a level many investors watch as a reference point for further upside.